RGNX

REGENXBIO Inc.

RGNX · CIK 1590877 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$83M
20172024
Net Income−$227M
20172024
Operating CF−$173M
20172024
Free Cash Flow−$176M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.1B$0.1B$0.1B$0.5B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B——
Gross Profit————————
R&D Expense$0.2B$0.2B$0.2B$0.2B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.2B$-0.3B$-0.3B$0.2B$-0.1B$-0.1B$0.1B$-0.1B
Net Income$-0.2B$-0.3B$-0.3B$0.1B$-0.0B$-0.0B$0.0B$-0.0B
EPS (Basic)$-4.59$-6.02$-6.50$3.01$-1.24$-0.72$0.12—
EPS (Diluted)$-4.59$-6.02$-6.50$2.91$-1.24$-0.72$0.11—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.5B$0.6B$0.8B$1.1B$0.7B$0.5B$0.5B$0.2B
Current Assets$0.3B$0.3B$0.4B$0.5B$0.5B$0.3B$0.3B$0.2B
Cash & Equivalents$0.1B$0.0B$0.1B$0.3B$0.3B$0.1B$0.1B$0.0B
Total Liabilities$0.2B$0.3B$0.3B$0.3B$0.3B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.3B$0.5B$0.8B$0.4B$0.5B$0.5B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.2B$-0.2B$-0.2B$0.2B$-0.1B$-0.1B$0.1B—
Investing Cash Flow$0.1B$0.2B$-0.0B$-0.4B$0.1B$0.1B$-0.3B—
Capital Expenditures$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$-0.0B$-0.0B$0.2B$0.2B$0.0B$0.2B—
← Companies